Suggested remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating enthesitis-related arthritis or juvenile psoriatic arthritis.
Following on from information received from the company, NICE has decided to suspend this technology appraisal from the current work programme and timelines are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
 
Status Suspended
Process STA 2018
ID number 3738

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 October 2021 Suspended. Following on from information received from the company, NICE has decided to suspend this technology appraisal from the current work programme and timelines are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
31 July 2020 - 28 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance